1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors

Patent metadata

Field	Value
Publication number	US-11053234-B2
Application number	US-201716341113-A
Country	US
Kind code	B2
Filing date	Oct 12, 2017
Priority date	Oct 13, 2016
Publication date	Jul 6, 2021
Grant date	Jul 6, 2021

Abstract

A compound of formula (I)

wherein R, R 1 , R 2 , R 3 , Y, Y 1 , a, X, and Z are as defined herein.

The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

First claim

The invention claimed is:

1. A compound which is:

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt thereof, of claim 1 and one or more pharmaceutically acceptable carriers or excipients.

3. A method for the treatment of a disorder in a human in which inhibition of H-PGDS is beneficial, comprising administering to the human in need thereof, a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, of claim 1 .

4. A method for the treatment of an allergic disease or an inflammatory condition selected from asthma, aspirin-exacerbated respiratory disease (AERD), cough, chronic obstructive pulmonary disease, chronic bronchitis, emphysema, bronchoconstriction, seasonal allergic rhinitis, perennial allergic rhinitis, vasomotor rhinitis, rhinoconjuctivitis, allergic conjunctivitis, food allergy, hypersensitivity lung diseases, eosinophilic syndromes, eosinophilic asthma, eosinophilic pneumonitis, eosinophilic oesophagitis, eosinophilic granuloma, delayed-type hypersensitivity disorders, atherosclerosis, rheumatoid arthritis, pancreatitis, gastritis, inflammatory bowel disease, osteoarthritis, psoriasis, sarcoidosis, pulmonary fibrosis, respiratory distress syndrome, bronchiolitis, sinusitis, cystic fibrosis, actinic keratosis, skin dysplasia, chronic urticaria, eczema dermatitis, atopic dermatitis and contact dermatitis in a human comprising administering to the human in need thereof, a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, of claim 1 .

5. A method for the treatment of a neuromuscular-related condition selected from: Duchenne muscular dystrophy (MD), Becker MD, Congenital MD (Fukuyama), Dreifuss MD, Limb girdle MD, Fascioscapulohumeral MD, DM1 Myotonic dystrophy type I, Steinert's Myotonic dystrophy type I, DM2 myotonic dystrophy type IL proximal myotonic myopathy Myotonic dystrophy type II, congenital myotonia, polymyositis, dermatomyositis, amyotrophic Lateral Sclerosis (ALS), muscle injury, surgery-related muscle injury, traumatic muscle injury, work-related skeletal muscle injury, overtraining-related muscle injury, muscle damage due to knee replacement, muscle damage due to anterior cruciate ligament (ACL) repair, muscle damage due to plastic surgery, muscle damage due to hip replacement surgery, muscle damage due to joint replacement surgery, muscle damage due to tendon repair surgery, muscle damage due to surgical repair of rotator cuff disease, muscle damage due to surgical repair of rotator cuff injury, muscle damage due to amputation, battlefield muscle injuries, auto accident-related muscle injuries, sports-related muscle injuries, muscle lacerations, traumatic injury due to blunt force contusions, traumatic injury due to shrapnel wounds, muscle pulls or tears, traumatic injury due to burns, acute muscle strains, chronic muscle strains, weight or force stress muscle injuries, repetitive stress muscle injuries, avulsion muscle injury, compartment syndrome, muscle injuries caused by highly repetitive motions, muscle injuries caused by forceful motions, muscle injuries caused by awkward postures, muscle injuries caused by prolonged and forceful mechanical coupling between the body and an object, muscle injuries caused by vibration, muscle injuries due to unrepaired or under-repaired muscle damage coincident with a lack of recovery or lack of an increase of physical work capacity, exercise-induced delayed onset muscle soreness (DOMS), wound healing and disuse atrophy in a human comprising administering to the human in need thereof, a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, of claim 1 .

6. A method for the treatment of Duchenne muscular dystrophy (MD) in a human in need thereof, comprising administering to the human a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, of claim 1 .

7. A compound which is:

8. A pharmaceutical composition comprising the compound of claim 7 and one or more pharmaceutically acceptable carriers or excipients.

9. A method for the treatment of a disorder in a human in which inhibition of H-PGDS is beneficial, comprising administering to the human in need thereof a therapeutically effective amount of the compound of claim 7 .

10. A method for the treatment of an allergic disease or an inflammatory condition selected from asthma, aspirin-exacerbated respiratory disease (AERD), cough, chronic obstructive pulmonary disease, chronic bronchitis, emphysema, bronchoconstriction, seasonal allergic rhinitis, perennial allergic rhinitis, vasomotor rhinitis, rhinoconjuctivitis, allergic conjunctivitis, food allergy, hypersensitivity lung diseases, eosinophilic syndromes, eosinophilic asthma, eosinophilic pneumonitis, eosinophilic oesophagitis, eosinophilic granuloma, delayed-type hypersensitivity disorders, atherosclerosis, rheumatoid arthritis, pancreatitis, gastritis, inflammatory bowel disease, osteoarthritis, psoriasis, sarcoidosis, pulmonary fibrosis, respiratory distress syndrome, bronchiolitis, sinusitis, cystic fibrosis, actinic keratosis, skin dysplasia, chronic urticaria, eczema dermatitis, atopic dermatitis and contact dermatitis in a human comprising administering to the human in need thereof a therapeutically effective amount of the compound of claim 7 .

11. A method for the treatment of a neuromuscular-related condition selected from: Duchenne muscular dystrophy (MD), Becker MD, Congenital MD (Fukuyama), Dreifuss MD, Limb girdle MD, Fascioscapulohumeral MD, DM1 Myotonic dystrophy type I, Steinert's Myotonic dystrophy type I, DM2 myotonic dystrophy type II, proximal myotonic myopathy myotonic dystrophy type II, congenital myotonia, polymyositis, dermatomyositis, amyotrophic Lateral Sclerosis (ALS), muscle injury, surgery-related muscle injury, traumatic muscle injury, work-related skeletal muscle injury, overtraining-related muscle injury, muscle damage due to knee replacement, muscle damage due to anterior cruciate ligament (ACL) repair, muscle damage due to plastic surgery, muscle damage due to hip replacement surgery, muscle damage due to joint replacement surgery, muscle damage due to tendon repair surgery, muscle damage due to surgical repair of rotator cuff disease, muscle damage due to surgical repair of rotator cuff injury, muscle damage due to amputation, battlefield muscle injuries, auto accident-related muscle injuries, sports-related muscle injuries, muscle lacerations, traumatic injury due to blunt force contusions, traumatic injury due to shrapnel wounds, muscle pulls or tears, traumatic injury due to burns, acute muscle strains, chronic muscle strains, weight or force stress muscle injuries, repetitive stress muscle injuries, avulsion muscle injury, compartment syndrome, muscle injuries caused by highly repetitive motions, muscle injuries caused by forceful motions, muscle injuries caused by awkward postures, muscle injuries caused by prolonged and forceful mechanical coupling between the body and an object, muscle injuries caused by vibration, muscle injuries due to unrepaired or under-repaired muscle damage coincident with a lack of recovery or lack of an increase of physical work capacity, exercise-induced delayed onset muscle soreness (DOMS), wound healing and disuse atrophy in a human comprising administering to the human in need thereof, a therapeutically effective amount of the c

Assignees

• Glaxosmithkline Ip Dev Ltd

Inventors

• Deaton David Norman
• Guo Yu
• Hancock Ashley Paul
• Schulte Christie
• Shearer Barry George
• Smith Emilie Despagnet
• Stewart Eugene L
• Thomson Stephen Andrew

Classifications

• C07D277/44

  Acylated amino or imino radicals · CPC title

• C07D205/04 Primary

  having no double bonds between ring members or between ring members and non-ring members · CPC title

• C07D257/06

  with nitrogen atoms directly attached to the ring carbon atom · CPC title

• C07C2601/04

  with a four-membered ring · CPC title

• C07D239/42

  One nitrogen atom (nitro radicals C07D239/30) · CPC title